Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. There are currently few available therapies to treat and prevent the severe consequences of this disease, which affects as much as 10 percent of the world's population.
The company has two major programs; its lead program targets acute kidney injury (AKI). AKI is the sudden loss of kidney function that afflicts more than 1.2 million people each year in the United States and can lead to kidney failure and dialysis. The company's second program addresses diabetic nephropathy—a leading cause of chronic kidney disease (CKD) that can result in permanent loss of kidney function and the need for dialysis.
|03•31•15||Thrasos Secures $21 Million to Complete Phase 2 Study of THR-184 in the Prevention of Acute Kidney Injury and Expand the Company’s Renal Portfolio more >|
|09•06•14||Thrasos Announces Successful Formal Interim Analysis and Clinical Update for Phase 2 Study of THR-184 for Acute Kidney Injury more >|
|08•12•14||Thrasos Appoints Gaétan Gravel and Joseph Zakrzewski to Board of Directors more >|